

Christopher Bowen Managing Director and Chief Regulatory Coursel Legal Department

November 18, 2013

VIA E-MAIL

Ms. Melissa Jurgens Office of the Secretariat Commodity Futures Trading Commission Three Lafayette Centre 1155 21st Street, N.W. Washington, D.C. 20581

CONFIDENTIAL TREATHENT REQUESTED

RE: SUPPLEMENTAL SUBMISSION: NYMEX Submission No. 13-449S: Additional Supplemental Information Relating to Legacy GreenX Volume and Liquidity Provider Program. Subject to Freedom of Information Act Protection.

Dear Ms. Jurgens:

Previously, pursuant to Submission No. 13-449, New York Mercantile Exchange, Inc. ("NYMEX" or the "Exchange") notified the Commodity Futures Trading Commission ("CFTC" or "Commission") of modifications to the Legacy GreenX Volume and Liquidity Provider Program ("Program").

In this letter, NYMEX is providing the Commission with certain additional information related to the Program. The additional supplemental information is provided in Appendix A, for which a request for confidential treatment in accordance with the Freedom of Information Act is being simultaneously submitted to the Commission. A copy of that request for confidential treatment is being included with this supplemental filing.

The modifications appear below, with additions <u>underscored</u> and deletions overstruck.

NYMEX certifies that the Program complies with the Commodity Exchange Act and the regulations thereunder. A concise explanation and analysis of the operation, purpose and effect of the Program was provided in Submission No. 13-449. There were no substantive opposing views to this Program.

The Exchange certifies that a description of this submission has been concurrently posted on the Exchange's website at <u>http://www.cmegroup.com/market-regulation/rule-filings.html</u>.

If you require any additional information regarding this submission, please contact Tim Elliott at 312-466-7478 or via e-mail at <u>tim.elliott@cmegroup.com</u>, or contact me at 212-299-2200. Please reference our NYMEX Submission No. 13-449S in any related correspondence.

Sincerely,

/s/ Christopher K. Bowen Managing Director and Chief Regulatory Counsel

Attachment: Appendix A

1 North End Avenue New York, NY 10282 T 212 299 2200 F 212 299 2299 christopher.bowen@cmegroup.com cmegroup.com



Christopher Bowen Managing Director and Chief Regulatory Counsel Legal Department

November 18, 2013

VIA E-MAIL

Ms. Melissa Jurgens Office of the Secretariat Commodity Futures Trading Commission Three Lafayette Centre 1155 21st Street, N.W. Washington, D.C. 20581

CONFIDENTIAL TREATMENT REQUESTED

Re: FOIA Confidential Treatment Request

Dear Ms. Jurgens:

By e-mail dated today, November 18, 2013, the New York Mercantile Exchange, Inc. ("NYMEX" or the "Exchange") submitted a supplemental rule certification filing (Submission No. 13-449S) to the Commodity Futures Trading Commission ("CFTC" or "Commission"). This supplemental filing includes an appendix ("Appendix A"), which is attached.

Pursuant to Sections 8 and 8(a) of the Commodity Exchange Act ("CEA"), as amended, and Commission Regulation 145.9(d), NYMEX requests confidential treatment of Appendix A on the grounds that Appendix A contains confidential commercial information of the submitter (NYMEX). A detailed written justification support the request is attached hereto. Pursuant to Commission Regulation 145.9(d)(5), NYMEX requests that confidential treatment be maintained for Appendix A <u>until further notice from the Exchange</u>. We also request that the Commission notify the undersigned immediately after receiving any FOIA request for said Appendix A or any other court order, subpoena or summons for same. Finally, we request that we be notified in the event the Commission intends to disclose such Appendix A to Congress or to any other governmental agency or unit pursuant to Section 8 of the CEA. NYMEX does not waive its notification rights under Section 8(f) of the CEA with respect to any subpoena or summons for such Appendix A.

Please contact the undersigned at (212) 299-2200 should you have any questions concerning this letter.

Sincerely,

/s/ Christopher K. Bowen Managing Director and Chief Regulatory Counsel

Enclosure: Exhibit 1